Company Profile
BroadOak Capital Partners is a boutique financial institution specializing in the life sciences sector, offering both direct investment through BroadOak Asset Management and investment banking services via BroadOak Partners. The firm focuses on providing growth capital and advisory solutions to companies operating in life sciences tools, diagnostics, and biopharma services. Since its inception, BroadOak has made investments in over 70 companies and advised on more than 50 successful M&A transactions, demonstrating a robust track record in its niche market.
The firm was founded in 2006 by Bill Snider and Lars Hanan with a mission to serve life sciences companies that are often overlooked or underserved by traditional financial institutions. BroadOak aims to be a true partner, leveraging its deep industry expertise and extensive network to help businesses achieve their full potential.
BroadOak's investment portfolio includes a diverse range of life sciences companies such as Axol Bioscience, Harvard Bioscience, Pluristyx, PAK BioSolutions, EpiCypher, IC Biomedical, Azure Biosystems, Vida, Hudson Lab Automation, Horizon Infusions, BioCare Medical, Microsize, Indee Labs, PhenoVista, and Quartzy. The firm actively supports commercial-stage companies, often being the first institutional investor, and has recently expanded its investment platform with over $200 million in permanent capital and the closing of BroadOak Income Fund and initial closing for Fund VI.
The BroadOak team comprises experienced professionals with deep networks and a strong commitment to their clients and portfolio companies. Key team members include partners Bill Snider, D. Kyle Wilson, Tim Johnson, Lars Hanan, and Matt McFarland, along with operating partners and managing directors who bring extensive experience in M&A, private equity, operating roles, and growth capital investing within the healthcare and life sciences sectors.
News & Signals (0)
No linked news activity found for this company.